A Critical Assessment of Research on Neurotransmitters in Alzheimer's Disease
- PMID: 28409748
- PMCID: PMC5791142
- DOI: 10.3233/JAD-170256
A Critical Assessment of Research on Neurotransmitters in Alzheimer's Disease
Abstract
The purpose of this mini-forum, "Neurotransmitters and Alzheimer's Disease", is to critically assess the current status of neurotransmitters in Alzheimer's disease. Neurotransmitters are essential neurochemicals that maintain synaptic and cognitive functions in mammals, including humans, by sending signals across pre- to post-synaptic neurons. Authorities in the fields of synapses and neurotransmitters of Alzheimer's disease summarize the current status of basic biology of synapses and neurotransmitters, and also update the current status of clinical trials of neurotransmitters in Alzheimer's disease. This article discusses the prevalence, economic impact, and stages of Alzheimer's dementia in humans.
Keywords: Amyloid-β; cognitive decline; mitochondrial dysfunction; synaptic pathology.
Figures
References
-
- Toodayan N. Professor Alois Alzheimer (1864–1915): Lest we forget. J Clin Neurosci. 2016;31:47–55. - PubMed
-
- Glenner GG, Wong CW. Alzheimer’s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;425:534–539. - PubMed
-
- Montejo de Garcini E, Serrano L, Avila J. Self assembly of microtubule associated protein tau into filaments resembling those found in Alzheimer disease. Biochem Biophys Res Commun. 1986;141:790–796. - PubMed
-
- Avila J. Tau protein, the main component of paired helical filaments. J Alzheimers Dis. 2006;9:171–175. - PubMed
-
- Alzheimer’s Disease International. World Alzheimer Report. 2016 Available from: https://www.alz.co.uk/research/WorldAlzheimerReport2016.pdf.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical